Oral propranolol for retinopathy of prematurity

A small randomized trial from Italy allocated preterm infants (n = 52) with stage two retinopathy of prematurity (ROP) to either standard treatment or to treatment with oral propranolol plus standard treatment. Babies treated with propranolol had a lower rate of progression to more advanced stages of ROP and also needed laser or bevacizumab treatment less frequently. However more of the babies treated with propranolol had serious adverse effects such as hypotension and bradycardia.

Oral propranolol for retinopathy of prematurity. Filippi et al, 2013.